These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 25047665)

  • 1. Human papillomavirus infection in Bhutan at the moment of implementation of a national HPV vaccination programme.
    Tshomo U; Franceschi S; Dorji D; Baussano I; Tenet V; Snijders PJ; Meijer CJ; Bleeker MC; Gheit T; Tommasino M; Clifford GM
    BMC Infect Dis; 2014 Jul; 14():408. PubMed ID: 25047665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
    Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
    BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human papillomavirus infection in Rwanda at the moment of implementation of a national HPV vaccination programme.
    Ngabo F; Franceschi S; Baussano I; Umulisa MC; Snijders PJ; Uyterlinde AM; Lazzarato F; Tenet V; Gatera M; Binagwaho A; Clifford GM
    BMC Infect Dis; 2016 May; 16():225. PubMed ID: 27221238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human papillomavirus genotype distribution and socio-behavioural characteristics in women with cervical pre-cancer and cancer at the start of a human papillomavirus vaccination programme: the CIN3+ plus study.
    Egli-Gany D; Spaar Zographos A; Diebold J; Masserey Spicher V; Frey Tirri B; Heusser R; Dillner J; Petignat P; Sahli R; Low N;
    BMC Cancer; 2019 Jan; 19(1):111. PubMed ID: 30700274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of Human Papillomavirus and Estimation of Human Papillomavirus Vaccine Effectiveness in Thimphu, Bhutan, in 2011-2012 and 2018 : A Cross-sectional Study.
    Baussano I; Tshomo U; Tenet V; Heideman DAM; Wangden T; Franceschi S; Clifford GM
    Ann Intern Med; 2020 Dec; 173(11):888-894. PubMed ID: 32956600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of the HPV vaccination programme on incidence of cervical cancer and grade 3 cervical intraepithelial neoplasia by socioeconomic deprivation in England: population based observational study.
    Falcaro M; Soldan K; Ndlela B; Sasieni P
    BMJ; 2024 May; 385():e077341. PubMed ID: 38749552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urine testing to monitor the impact of HPV vaccination in Bhutan and Rwanda.
    Franceschi S; Chantal Umulisa M; Tshomo U; Gheit T; Baussano I; Tenet V; Tshokey T; Gatera M; Ngabo F; Van Damme P; Snijders PJ; Tommasino M; Vorsters A; Clifford GM
    Int J Cancer; 2016 Aug; 139(3):518-26. PubMed ID: 26991686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HPV16/18 prevalence in high-grade cervical lesions in an Australian population offered catch-up HPV vaccination.
    Cornall AM; Saville M; Pyman J; Callegari ET; Tan FH; Brotherton JML; Malloy MJ; Tabrizi SN; Wrede CD; Garland SM;
    Vaccine; 2020 Sep; 38(40):6304-6311. PubMed ID: 32736938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Human Papillomavirus Vaccination, Rwanda and Bhutan.
    Baussano I; Sayinzoga F; Tshomo U; Tenet V; Vorsters A; Heideman DAM; Gheit T; Tommasino M; Umulisa MC; Franceschi S; Clifford GM
    Emerg Infect Dis; 2021 Jan; 27(1):1-9. PubMed ID: 33350922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
    Lehtinen M; Paavonen J; Wheeler CM; Jaisamrarn U; Garland SM; Castellsagué X; Skinner SR; Apter D; Naud P; Salmerón J; Chow SN; Kitchener H; Teixeira JC; Hedrick J; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; De Carvalho NS; Germar MJ; Peters K; Mindel A; De Sutter P; Bosch FX; David MP; Descamps D; Struyf F; Dubin G;
    Lancet Oncol; 2012 Jan; 13(1):89-99. PubMed ID: 22075171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-vaccination type-specific HPV prevalence in confirmed cervical high grade lesions in the Māori and non-Māori populations in New Zealand.
    Kang YJ; Lewis H; Smith MA; Simonella L; Neal H; Bromhead C; Canfell K
    BMC Infect Dis; 2015 Aug; 15():365. PubMed ID: 26297490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study.
    Gertig DM; Brotherton JM; Budd AC; Drennan K; Chappell G; Saville AM
    BMC Med; 2013 Oct; 11():227. PubMed ID: 24148310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study.
    Falcaro M; Castañon A; Ndlela B; Checchi M; Soldan K; Lopez-Bernal J; Elliss-Brookes L; Sasieni P
    Lancet; 2021 Dec; 398(10316):2084-2092. PubMed ID: 34741816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High prevalence of high-risk HPV genotypes other than 16 and 18 in cervical cancers of Curaçao: implications for choice of prophylactic HPV vaccine.
    Hooi DJ; Lissenberg-Witte BI; de Koning MNC; Pinedo HM; Kenter GG; Meijer CJ; Quint WG
    Sex Transm Infect; 2018 Jun; 94(4):263-267. PubMed ID: 29021405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Type-specific HPV prevalence in invasive cervical cancer in the UK prior to national HPV immunisation programme: baseline for monitoring the effects of immunisation.
    Mesher D; Cuschieri K; Hibbitts S; Jamison J; Sargent A; Pollock KG; Powell N; Wilson R; McCall F; Fiander A; Soldan K
    J Clin Pathol; 2015 Feb; 68(2):135-40. PubMed ID: 25410654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human papillomavirus infection in women with and without cervical cancer in Tbilisi, Georgia.
    Alibegashvili T; Clifford GM; Vaccarella S; Baidoshvili A; Gogiashvili L; Tsagareli Z; Kureli I; Snijders PJ; Heideman DA; van Kemenade FJ; Meijer CJ; Kordzaia D; Franceschi S
    Cancer Epidemiol; 2011 Oct; 35(5):465-70. PubMed ID: 21292583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population-based prevalence, type- and age-specific distribution of HPV in women before introduction of an HPV-vaccination program in Denmark.
    Kjaer SK; Breugelmans G; Munk C; Junge J; Watson M; Iftner T
    Int J Cancer; 2008 Oct; 123(8):1864-70. PubMed ID: 18661520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of catch-up human papillomavirus vaccination on incident cervical neoplasia in a US health-care setting: a population-based case-control study.
    Silverberg MJ; Leyden WA; Lam JO; Gregorich SE; Huchko MJ; Kulasingam S; Kuppermann M; Smith-McCune KK; Sawaya GF
    Lancet Child Adolesc Health; 2018 Oct; 2(10):707-714. PubMed ID: 30236379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human papillomavirus in invasive cervical cancer and cervical intraepithelial neoplasia 2 and 3 in Venezuela: a cross-sectional study.
    Sánchez-Lander J; Cortiñas P; Loureiro CL; Pujol FH; Medina F; Capote-Negrín L; Bianchi G; García-Barriola V; Ruiz-Benni A; Avilán-Rovira J; Acosta H
    Cancer Epidemiol; 2012 Oct; 36(5):e284-7. PubMed ID: 22608058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.